Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#16403
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The companyโs lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$7.02
Last synced: 2026-11-09
Market Cap
$212.39M
Change (1 day)
-6.77%
Change (1 year)
-3.84%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
EPS for Cartesian Therapeutics, Inc. (RNAC)
EPS as of September 2026 TTM: $-4.93
According to Cartesian Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-4.93. At the end of 2025 the company had an EPS of $-5.02, a decrease compared to its 2024 EPS of $-3.29.
EPS history for Cartesian Therapeutics, Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.93 | -1.79% |
| 2025 | $-5.02 | 52.58% |
| 2024 | $-3.29 | -93.39% |
| 2023 | $-49.76 | -778.85% |
| 2022 | $7.33 | -208.75% |
| 2021 | $-6.74 | -66.99% |
| 2020 | $-20.42 | -43.99% |
| 2019 | $-36.46 | -58.36% |
| 2018 | $-87.55 | -8.75% |
| 2017 | $-95.94 | -7.32% |
| 2016 | $-103.52 | 36.59% |
| 2015 | $-75.79 | 98.56% |
| 2014 | $-38.17 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -417.65% |
US
|
|
| $-7.07 | 43.41% |
US
|
|
| $-5.29 | 7.30% |
AU
|
|
| $12.88 | -361.26% |
BE
|
|
| $21.56 | -537.32% |
NL
|
Questions about Cartesian Therapeutics, Inc.'s earnings per share (EPS)
What is Cartesian Therapeutics, Inc.'s earnings per share (EPS)?
Cartesian Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-4.93, as of Sep 2026.
What was Cartesian Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Cartesian Therapeutics, Inc.'s earnings per share (EPS) was $-5.02, compared with $-3.29 in 2024.
How has Cartesian Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cartesian Therapeutics, Inc.'s earnings per share (EPS) was highest in 2022 ($7.33) and lowest in 2023 ($-49.76).
How does Cartesian Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Cartesian Therapeutics, Inc.'s earnings per share (EPS) ($-4.93) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.